700 patients110,866 observations180 daysLIVE

Patient P-02035

Synthetic patientMETA-24 · Day 170 · 25–34 · F · baseline S19Open companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
59%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S19
  2. Day 70 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 76 GI-04 recommendedGI Support Protocol GI-04
  4. Day 77 Patient acceptedStarted GI-04 in the companion
  5. Day 85 GI symptom burden −27% vs expectedGI Support Protocol GI-04
  6. Day 91 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 70.

Primary contributors, last 14 days
  • Inflammatory activity-12
  • Treatment adherence-8
  • GI instability-4
  • Toxicity-4

What helped?

  • GI Support Protocol GI-04Day 76
    Result: symptom burden −27%
LIFE OS recommendation
Monitoring Escalation ME-01
80%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 45
    • WearableHRV 18 ms, trending down
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 34/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 20
    • Daily logGI symptom score 54 and rising
  • Drug metabolism and exposure 20
    • BloodToxicity index 43
  • Autonomic recovery 20
    • Wearable3,356 steps/day
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 34/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
20 ms
Sleep
7.1 h
Steps
3,530
Resting HR
67 bpm
Daily log: GI score 54, nutritional resilience 42, adherence 43.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0263354%S14NP-02improved48
P-0201449%S14GI-04improved48
P-0257446%S14ME-01improved45
P-0200245%S14GI-04improved47
P-0224145%S09GI-04improved56
P-0236345%S14GI-04improved49
P-0211844%S14GI-04improved47
P-0210842%S14GI-04improved43
P-0212542%S14GI-04improved55
P-0254242%S14NP-02improved44
P-0226841%S14GI-04improved43
P-0229741%S02NP-02improved49